Inflammation Cascade: Acute & Chronic Inflammatory Pathways

Clinical meaning

Inflammation is a complex, coordinated biological response to tissue injury, infection, or foreign substances that involves the vascular system, immune cells, and molecular mediators. The NP must understand the molecular cascade to interpret inflammatory biomarkers, select appropriate anti-inflammatory therapies, and differentiate physiological from pathological inflammation.

Acute Inflammation: The acute inflammatory response is initiated within seconds to minutes of tissue injury and involves three primary phases: vascular changes, cellular recruitment, and resolution. Tissue-resident macrophages and mast cells serve as sentinels, detecting damage-associated molecular patterns (DAMPs) from injured cells (ATP, HMGB1, uric acid crystals) and pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (TLRs, NOD-like receptors). Mast cell degranulation releases preformed mediators — histamine, serotonin, and TNF-α — causing immediate arteriolar vasodilation and increased vascular permeability. Histamine acts on H1 receptors on endothelial cells, causing contraction of endothelial cells and widening of intercellular gaps, allowing protein-rich exudate to leak into the interstitium. This produces the cardinal signs of inflammation: rubor (redness from vasodilation), calor (heat from increased blood flow), tumor (swelling from edema), dolor (pain from bradykinin and prostaglandins sensitizing nociceptors), and functio laesa (loss of function).

The arachidonic acid (AA) cascade is central to inflammatory amplification. Phospholipase A2 (PLA2) liberates AA from membrane phospholipids. The cyclooxygenase (COX) pathway produces prostaglandins (PGE2 — vasodilation, fever, pain sensitization; PGI2/prostacyclin — vasodilation and anti-platelet) and thromboxane A2 (TXA2 — vasoconstriction and platelet aggregation). COX-1 is constitutive (housekeeping: gastric mucosal protection via PGE2, platelet TXA2 production, renal blood flow maintenance). COX-2 is inducible (upregulated during inflammation, producing inflammatory prostaglandins). The lipoxygenase (LOX) pathway produces leukotrienes: LTB4 is a potent neutrophil chemoattractant, while LTC4, LTD4, and LTE4 (cysteinyl leukotrienes) cause bronchoconstriction, increased vascular permeability, and mucus secretion — these are the mediators of asthma.

Diagnosis & workup

Diagnostics & workup: - C-reactive protein (CRP): acute-phase reactant synthesized by hepatocytes in response to IL-6; rises within 6-8 hours of inflammatory stimulus, peaks at 48 hours; half-life 19 hours; highly sensitive but nonspecific; high-sensitivity CRP (hs-CRP) used for cardiovascular risk stratification (<1 mg/L low risk, 1-3 mg/L intermediate, >3 mg/L high risk) - Erythrocyte sedimentation rate (ESR): measures rate of RBC settling; elevated in inflammation due to increased fibrinogen and immunoglobulins altering RBC surface charge; rises slowly (days), falls slowly; useful for monitoring chronic inflammatory conditions (temporal arteritis, polymyalgia rheumatica) - Procalcitonin (PCT): precursor of calcitonin released by thyroid C cells and neuroendocrine cells in response to bacterial toxins and pro-inflammatory cytokines; elevated in bacterial infection (>0.5 ng/mL suggests bacterial etiology), remains low in viral infections and autoimmune flares; guides antibiotic initiation and discontinuation - Ferritin: acute-phase reactant markedly elevated in systemic inflammation (macrophage activation syndrome, hemophagocytic lymphohistiocytosis, adult-onset Still disease); ferritin >10,000 ng/mL has 90% specificity for HLH; also elevated in iron overload — clinical context determines interpretation - Complete blood count with differential: leukocytosis with neutrophilia (acute bacterial inflammation), lymphocytosis (viral/chronic), eosinophilia (allergic/parasitic), monocytosis (chronic granulomatous); leukopenia may occur in overwhelming sepsis or autoimmune conditions - Complement levels (C3, C4, CH50): consumed in immune complex-mediated inflammation (lupus nephritis, post-streptococcal GN); low C3/C4 indicates active complement-mediated disease; CH50 measures total complement pathway function - Autoantibody panel as indicated: ANA (systemic lupus), RF and anti-CCP (rheumatoid arthritis), ANCA (vasculitis), anti-dsDNA and anti-Smith (lupus specificity) - Cytokine panels (research/specialized settings): IL-6, TNF-α, IL-1β, IL-10 — increasingly used in critical care (cytokine storm assessment) and rheumatology

Risk factors: - Autoimmune predisposition: genetic susceptibility (HLA associations), female sex (70-80% of autoimmune disease occurs in women), family history of autoimmune disorders - Chronic infections: persistent bacterial, viral, or parasitic infections that sustain inflammatory signaling (hepatitis B/C, H. pylori, tuberculosis) - Obesity: visceral adipose tissue is metabolically active, secreting pro-inflammatory adipokines (TNF-α, IL-6, leptin) creating chronic low-grade systemic inflammation - Smoking: activates alveolar macrophages, increases oxidative stress, promotes NF-κB activation, and is a major driver of chronic inflammation in COPD, atherosclerosis, and rheumatoid arthritis - Aging (inflammaging): progressive increase in circulating pro-inflammatory cytokines (IL-6, TNF-α, CRP) with advancing age, driven by cellular senescence, altered gut microbiome, and declining anti-inflammatory mechanisms - Environmental exposures: asbestos, silica, air pollution, and other inhaled particulates cause persistent macrophage activation and granulomatous inflammation - Chronic stress and sleep deprivation: cortisol dysregulation, sympathetic activation, and impaired resolution of inflammation through neuroendocrine pathways - Dysbiosis: disrupted gut microbiome composition increases intestinal permeability (leaky gut), allowing translocation of bacterial products (LPS) that activate systemic inflammation

Clinical meaning

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT

Diagnosis & workup

Management

Prescribing & monitoring

Takeaways

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT

Clinical meaning

Practice questions for this topic

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT

Diagnosis & workup

Practice questions for this topic

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT